1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Infliximab Formulation

Manufacturer or supplier’s details
Company: MSD
Address: JL Raya Pandaan KM. 48
          Pandaan, Jawa Timur - Indonesia
Telephone: 908-740-4000
Emergency telephone number: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>&gt;= 60 -&lt;= 100</td>
</tr>
<tr>
<td>Infliximab</td>
<td>170277-31-3</td>
<td>&gt;= 10 -&lt; 30</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders:
No special precautions are necessary for first aid responders.

Notes to physician:
Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media:
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during firefighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters:
Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>NAB</td>
<td>10 mg/m³</td>
<td>ID OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infliximab</td>
<td>170277-31-3</td>
<td>TWA</td>
<td>150 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further information: Adopted in Year 1996, Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Engineering measures: Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are de-
signed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

**Personal protective equipment**

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - **Filter type**: Particulates type

- **Hand protection**: Chemical-resistant gloves

- **Remarks**: For prolonged or repeated contact use protective gloves. Wash hands before breaks and at the end of workday.

- **Eye protection**: Wear the following personal protective equipment:
  - Safety goggles

- **Skin and body protection**: Skin should be washed after contact.
  - **Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

---

**9. PHYSICAL AND CHEMICAL PROPERTIES**

- **Appearance**: Amorphous powder
- **Colour**: white
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: 7.2
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
SAFETY DATA SHEET

Infliximab Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.14</td>
<td>09/13/2019</td>
<td>19272-00015</td>
<td>2019/04/24</td>
<td>2014/10/07</td>
</tr>
</tbody>
</table>

flammability limit

Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : 1 g/cm³

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac-
tions : May form explosive dust-air mixture during processing, han-
dling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoiding dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
                                      Skin contact
                                      Ingestion
                                      Eye contact

Acute toxicity
Not classified based on available information.
Components:

Sucrose:
Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Infliximab:
Remarks : No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Infliximab:
Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Sucrose:
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Infliximab:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: Chromosomal aberration
Test system: human lymphoblastoid cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Method: OECD Test Guideline 474
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.
Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

**Infliximab:**

Effects on fertility:
- Test Type: Fertility
- Species: Mouse
- Application Route: Intravenous injection
- Fertility: NOAEL: 40 mg/kg body weight
- Remarks: Based on data from similar materials

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Mouse, female
- Application Route: Intravenous injection
- Duration of Single Treatment: 6 - 12 d
- General Toxicity Maternal: NOAEL: 40 mg/kg body weight
- Teratogenicity: NOAEL F1: 40 mg/kg body weight
- Developmental Toxicity: NOAEL F1: 40
- Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight
- Remarks: Based on data from similar materials

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
Not classified based on available information.

**Repeated dose toxicity**

Components:

**Infliximab:**
- Species: Mouse
- NOAEL: 40 mg/kg
- Application Route: Intravenous
- Exposure time: 6 Months
- Number of exposures: daily

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

Components:

**Infliximab:**
- Inhalation: Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, Fatigue, Headache, Back pain
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Infliximab:

Ecotoxicology Assessment
Acute aquatic toxicity : No data available
Chronic aquatic toxicity : No data available

Persistence and degradability
No data available

Bioaccumulative potential

Components:

Sucrose:
Partition coefficient: n-octanol/water : Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.
15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health
Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances
Hazardous substances approved for use : Not applicable
Prohibited substances : Not applicable
Restricted substances : Not applicable

Regulation of the Minister of Trade No. 44 of 2009 on Procurement, Distribution and Supervision of Hazardous Materials
Type of Hazardous Materials Restricted to Import, Distribution and Supervision : Not applicable

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information

Date format : yyyy/mm/dd

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ID OEL : Indonesia. Occupational Exposure Limits
ACGIH / TWA : 8-hour, time-weighted average
ID OEL / NAB : Long term exposure limit
SAFETY DATA SHEET

Infliximab Formulation

Version 1.14  Revision Date: 09/13/2019  SDS Number: 19272-00015  Date of last issue: 2019/04/24  Date of first issue: 2014/10/07

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN